Understanding the role of specific T cells in lupus
Origin and Function of Double Negative T cells in Lupus
This study is looking into a special type of immune cell called double-negative T cells to see how they might play a role in lupus and help create harmful antibodies, with the hope of finding new ways to treat the condition and improve understanding for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project ID | NIH-10974476 on NIH RePORTER |
What this research studies
This research investigates the origin and function of double-negative T cells, a unique type of immune cell, in the context of Systemic Lupus Erythematosus (SLE). The study aims to uncover how these T cells contribute to the generation of auto-reactive plasma cells that produce harmful auto-antibodies. By examining the signals that control the formation and maintenance of these T cells, the research seeks to identify potential therapeutic targets for treating lupus. Patients may benefit from a better understanding of their condition and the development of new treatment strategies.
Who could benefit from this research
Good fit: Ideal candidates for participation are individuals diagnosed with Systemic Lupus Erythematosus, particularly those experiencing active disease.
Not a fit: Patients with lupus who are in remission or those with other autoimmune conditions unrelated to the mechanisms being studied may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that specifically target the immune mechanisms driving lupus, potentially improving patient outcomes.
How similar studies have performed: While the role of T follicular helper cells in lupus has been studied, the specific investigation of double-negative T cells is relatively novel and has not been extensively tested.
Where this research is happening
Birmingham, United States
- University of Alabama at Birmingham — Birmingham, United States (Active)
Researchers
- Principal investigator: Randall, Troy D — University of Alabama at Birmingham
- Study coordinator: Randall, Troy D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.